Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06744920 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06744920: Recruiting Phase 3 study of Generalized Myasthenia Gravis, sponsored by Novartis Pharmaceuticals.
NCT06744920 is a Phase 3 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 180 participants, above the 124-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06744920, a Phase 3 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
Primary Outcome
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Remibrutinib (Blinded)
- DRUG Remibrutinib (Open Label)
Study Locations (20)
Florida
- SFM Clinical Research LLC - Boca Raton
- Homestead Assoc In Research Inc - Homestead
- AdventHealth - Orlando
- Neurological Services of Orlando PA - Orlando
California
- Fullerton Neuro and Headache Ctr - Fullerton
- University Of Southern California - Los Angeles
- Univ Cali Irvine ALS Neuromuscular - Orange
Arizona
- Neuromuscular Research Center - Phoenix
- Honor Health Research Institute - Scottsdale
Texas
- Houston Methodist Hospital - Houston
- UT Health Science Center - Houston
Maryland
- Mid Atlantic Epilepsy and Sleep Ctr - Bethesda
Michigan
- Michigan State University-Department of Neurology - East Lansing
New York
- Dent Neurological Institute - Buffalo
Ohio
- Univ of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-02-07 |
| Est. Completion | 2033-02-26 |
| Phase | Phase 3 |
What NCT06744920 shows while recruiting
NCT06744920 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 124-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06744920 names 20 study sites across 13 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06744920 about?
NCT06744920 is a clinical study titled "A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis". A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
What is the current status of trial NCT06744920?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2025-02-07. Estimated completion is 2033-02-26.
What conditions does trial NCT06744920 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT06744920?
The interventions under investigation include: Placebo (OTHER), Remibrutinib (Blinded) (DRUG), Remibrutinib (Open Label) (DRUG).
Who is sponsoring clinical trial NCT06744920?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06744920 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06744920's enrollment target sits among peer trials
180 9th of 26 higher than 17 of 26 other Generalized Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI